Major depressive disorder (MDD) is one of the most common psychiatric conditions in the United States and a leading cause of disability worldwide. Per the National Institute of Mental Health, an estimated 8.3% of U.S. adults (approximately 21 million people) experienced at least one major depressive episode in a given year. Lifetime prevalence is approximately 20%.
Per recent CDC NHANES data (2021-2023), depression prevalence in adolescents and adults age 12 and older has risen from 8.2% (2013-2014) to 13.1% (2021-2023) — a substantial increase reflecting both real increase and improved recognition.
Depression is a medical condition with identified neurobiology and well-established evidence-based treatments. It’s not weakness, character flaw, or simply “feeling sad” — and most patients improve substantially with appropriate care.
DSM-5-TR Criteria for Major Depressive Disorder
MDD requires 5 or more of the following symptoms during a 2-week period, with at least one being depressed mood or loss of interest/pleasure:
- Depressed mood most of the day, nearly every day
- Markedly diminished interest or pleasure (anhedonia) in nearly all activities
- Significant weight loss or gain, or appetite changes
- Insomnia or hypersomnia nearly every day
- Psychomotor agitation or retardation observable by others
- Fatigue or loss of energy
- Feelings of worthlessness or excessive/inappropriate guilt
- Diminished ability to think or concentrate, or indecisiveness
- Recurrent thoughts of death, suicidal ideation, or suicide attempt
Symptoms must cause clinically significant distress or impairment and not be attributable to substances, medical conditions, or other mental disorders.
Who’s Affected
Per NIMH and SAMHSA data:
- Women are affected at approximately twice the rate of men
- Young adults (18-25) have higher prevalence than older adults
- Approximately 60% of adults with major depressive episode receive treatment
- Per CDC NHANES data, depression prevalence is approximately three times higher in those from families in the lowest income level compared to highest
- Depression is the leading cause of disability in the U.S. for ages 15-44 per WHO and other sources
Common Misconceptions
“It’s just sadness”
Major depression involves persistent changes in mood, energy, sleep, appetite, cognition, and physical functioning — not transient sadness.
“I just need to think positive”
Depression involves measurable changes in brain function. Willpower alone rarely produces remission, just as willpower doesn’t cure hypothyroidism.
“Medication just masks the problem”
Evidence-based antidepressant treatment addresses the underlying neurobiology — not just symptoms. Many patients achieve complete remission with appropriate treatment.
“Depression is a sign of weakness”
Depression is a medical condition like diabetes or hypertension. It has biological, psychological, and social contributors. It’s not a character flaw.
Evidence-Based Treatment
First-line medications
Per APA practice guidelines:
- SSRIs — sertraline, escitalopram, fluoxetine, paroxetine, citalopram
- SNRIs — venlafaxine, duloxetine, desvenlafaxine, levomilnacipran
- Bupropion — different mechanism; useful for atypical depression, low energy, and to avoid sexual side effects
- Mirtazapine — useful for depression with significant insomnia or appetite loss
- Most patients see meaningful improvement within 2-4 weeks, with substantial response by 6-8 weeks at adequate doses
STAR*D Trial Findings
The landmark Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial — the largest practical depression trial ever conducted — found:
- Level 1 (initial SSRI): approximately 28-33% remission per QIDS-SR scoring
- Approximately 47% response (defined as ≥50% symptom reduction)
- Level 2 (switch or augment): additional approximately 31% of remaining patients achieved remission
- Cumulative remission rate after four sequential treatment trials: theoretical 67% in original analysis; subsequent reanalyses suggest 35-50% with conservative methodology
These findings emphasize that depression treatment often requires sequential approaches — not every patient responds to the first medication trial.
Psychotherapy
- Cognitive Behavioral Therapy (CBT) — Strong evidence; effective alone for mild-moderate depression
- Interpersonal Therapy (IPT) — Evidence-based; focuses on relationships and role transitions
- Behavioral Activation — Particularly effective for depression with prominent anhedonia and withdrawal
- Mindfulness-Based Cognitive Therapy (MBCT) — Evidence for relapse prevention
Combined treatment
For moderate-to-severe depression, medication plus psychotherapy typically produces better outcomes than either alone.
Advanced treatments
For treatment-resistant cases:
- Esketamine (Spravato) — FDA-approved 2019 for TRD; rapid antidepressant effects
- Repetitive Transcranial Magnetic Stimulation (TMS) — FDA-approved; non-invasive
- Electroconvulsive Therapy (ECT) — Highly effective for severe and treatment-resistant cases
- Augmentation strategies — Lithium, atypical antipsychotics, T3 thyroid hormone
Source: Rush et al. (2006), STAR*D trial; NIMH data.
Inadequate treatment
Many patients receive subtherapeutic doses, inadequate duration, or stop after first medication failure — missing opportunities for full remission.
Evidence-based sequential treatment
Dr. Farkas uses measurement-based care (PHQ-9 tracking) and evidence-based sequential strategies to achieve full remission.
Real remission
Most patients achieve documented full remission with appropriate sequential treatment — not just “feeling better” but actually well.
Common Questions About Major Depression
How is depression diagnosed?
Depression diagnosis requires comprehensive clinical evaluation against DSM-5-TR criteria. The PHQ-9 screening tool developed by Kroenke and colleagues (2001) provides validated severity measurement — a score of 10 or higher has approximately 88% sensitivity and 88% specificity for major depression. Diagnosis requires clinical evaluation considering history, examination, and differential diagnosis.
Will I need to take antidepressants forever?
Not necessarily. For first depressive episodes, treatment is typically continued 6-12 months after remission. For recurrent depression, longer-term or indefinite treatment may produce better long-term outcomes. Decisions are individualized.
How long until antidepressants work?
Initial effects often emerge within 2-4 weeks. Full response typically requires 6-8 weeks at adequate dose. If insufficient response by 8-12 weeks, treatment adjustment is typically warranted. See our related articles on antidepressants and treatment-resistant depression.
What about therapy alone without medication?
For mild-to-moderate depression, evidence-based therapy (CBT, IPT, behavioral activation) alone can be effective. For severe depression, combination treatment typically works better. Therapy alone is reasonable as initial approach for many patients with milder presentations.